117 related articles for article (PubMed ID: 12753318)
21. Effect of pamidronate on new vertebral fractures and bone mineral density in patients with malignant lymphoma receiving chemotherapy.
Kim SH; Lim SK; Hahn JS
Am J Med; 2004 Apr; 116(8):524-8. PubMed ID: 15063813
[TBL] [Abstract][Full Text] [Related]
22. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial.
Boutsen Y; Jamart J; Esselinckx W; Stoffel M; Devogelaer JP
Calcif Tissue Int; 1997 Oct; 61(4):266-71. PubMed ID: 9312195
[TBL] [Abstract][Full Text] [Related]
23. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.
Deane A; Constancio L; Fogelman I; Hampson G
BMC Musculoskelet Disord; 2007 Jan; 8():3. PubMed ID: 17214897
[TBL] [Abstract][Full Text] [Related]
24. Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate.
Trombetti A; Gerbase MW; Spiliopoulos A; Slosman DO; Nicod LP; Rizzoli R
J Heart Lung Transplant; 2000 Aug; 19(8):736-43. PubMed ID: 10967266
[TBL] [Abstract][Full Text] [Related]
25. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate.
Kananen K; Volin L; Laitinen K; Alfthan H; Ruutu T; Välimäki MJ
J Clin Endocrinol Metab; 2005 Jul; 90(7):3877-85. PubMed ID: 15797959
[TBL] [Abstract][Full Text] [Related]
26. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate.
Bianda T; Linka A; Junga G; Brunner H; Steinert H; Kiowski W; Schmid C
Calcif Tissue Int; 2000 Aug; 67(2):116-21. PubMed ID: 10920215
[TBL] [Abstract][Full Text] [Related]
27. Evolution of bone disease at 2 years after transplantation: a single-center study.
Falkiewicz K; Boratyńska M; Zmonarski SC; Milewicz A; Patrzałek D; Biecek P; Klinger M
Transplant Proc; 2009 Oct; 41(8):3063-6. PubMed ID: 19857677
[TBL] [Abstract][Full Text] [Related]
28. Loss of regional bone mineral density in the first 12 months following renal transplantation.
Almond MK; Kwan JT; Evans K; Cunningham J
Nephron; 1994; 66(1):52-7. PubMed ID: 8107953
[TBL] [Abstract][Full Text] [Related]
29. Bone loss in long-term renal transplantation: histopathology and densitometry analysis.
Cueto-Manzano AM; Konel S; Hutchison AJ; Crowley V; France MW; Freemont AJ; Adams JE; Mawer B; Gokal R
Kidney Int; 1999 May; 55(5):2021-9. PubMed ID: 10231467
[TBL] [Abstract][Full Text] [Related]
30. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis.
Cauza E; Etemad M; Winkler F; Hanusch-Enserer U; Partsch G; Noske H; Dunky A
J Clin Pharm Ther; 2004 Oct; 29(5):431-6. PubMed ID: 15482386
[TBL] [Abstract][Full Text] [Related]
31. Alendronate prevents further bone loss in renal transplant recipients.
Giannini S; D'Angelo A; Carraro G; Nobile M; Rigotti P; Bonfante L; Marchini F; Zaninotto M; Dalle Carbonare L; Sartori L; Crepaldi G
J Bone Miner Res; 2001 Nov; 16(11):2111-7. PubMed ID: 11697808
[TBL] [Abstract][Full Text] [Related]
32. Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety.
Ryan PJ; Blake GM; Davie M; Haddaway M; Gibson T; Fogelman I
Osteoporos Int; 2000; 11(2):171-6. PubMed ID: 10793877
[TBL] [Abstract][Full Text] [Related]
33. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
34. Mineral density gain in vertebrae of osteoporotic women on oral pamidronate reverts a year after treatment discontinuance.
Zanchetta JR; Plotkin H; Roldán EJ
Calcif Tissue Int; 1996 Jul; 59(1):70-2. PubMed ID: 8661988
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation.
Ebeling PR; Thomas DM; Erbas B; Hopper JL; Szer J; Grigg AP
J Bone Miner Res; 1999 Mar; 14(3):342-50. PubMed ID: 10027899
[TBL] [Abstract][Full Text] [Related]
36. Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study.
Plotkin H; Coughlin S; Kreikemeier R; Heldt K; Bruzoni M; Lerner G
Dev Med Child Neurol; 2006 Sep; 48(9):709-12. PubMed ID: 16904014
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation.
Aris RM; Lester GE; Renner JB; Winders A; Denene Blackwood A; Lark RK; Ontjes DA
Am J Respir Crit Care Med; 2000 Sep; 162(3 Pt 1):941-6. PubMed ID: 10988110
[TBL] [Abstract][Full Text] [Related]
38. Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest.
Watanabe Y; Ohshima H; Mizuno K; Sekiguchi C; Fukunaga M; Kohri K; Rittweger J; Felsenberg D; Matsumoto T; Nakamura T
J Bone Miner Res; 2004 Nov; 19(11):1771-8. PubMed ID: 15476576
[TBL] [Abstract][Full Text] [Related]
39. Bone mineral density in the long term after liver transplantation.
Hamburg SM; Piers DA; van den Berg AP; Slooff MJ; Haagsma EB
Osteoporos Int; 2000; 11(7):600-6. PubMed ID: 11069194
[TBL] [Abstract][Full Text] [Related]
40. Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation.
Goffin E; Devogelaer JP; Lalaoui A; Depresseux G; De Naeyer P; Squifflet JP; Pirson Y; van Ypersele de Strihou C
Transpl Int; 2002 Mar; 15(2-3):73-80. PubMed ID: 11935163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
